Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...

Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a ...

On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...

Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...

Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss treatments, but the ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Cambridge, USA-based Korro Bio has entered a collaboration with Denmark’s Novo Nordisk to advance the discovery and ...

There are currently no pharmaceutical treatments approved for general obesity in under-12s — as opposed to that found with some rare genetic disorders — said Claudia Fox, a professor from University ...

Sun Pharma of India and Mylan Pharmaceuticals of West Virginia seek FDA approval of generic versions of the popular ...

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...